Literature DB >> 17475942

Six-year incidence of proteinuria in type 1 diabetic African Americans.

Monique S Roy1, Mahmoud Affouf, Alec Roy.   

Abstract

OBJECTIVE: We sought to report the 6-year incidence of proteinuria and associated risk factors in African Americans with type 1 diabetes. RESEARCH DESIGN AND METHODS: African Americans (n = 483) with type 1 diabetes were reexamined in a 6-year follow-up study. Proteinuria and creatinuria were measured in 4-h timed urine specimens obtained at initial and follow-up visits. Other evaluations included a structured clinical interview, ocular examination, masked grading of seven stereoscopic fundus photographs, blood pressure measurements, blood assays, and administration of the Beck Depression Inventory (BDI).
RESULTS: Over the 6-year period, 117 (42.9%) of the 473 patients at risk developed "any" proteinuria, defined as either microalbuminuria (26.0%) or overt (16.9%) proteinuria; 87 (23.5%) progressed from micro- or no albuminuria to overt proteinuria and 39 (8.7%) to end-stage renal disease; and 40 (20.6%) regressed. Peak incidence of any proteinuria occurred for patients who were 10-14 years of age or had 5-10 years of diabetes duration at baseline. Multiple regression analysis showed that baseline albumin excretion rate (AER), systemic hypertension, blood cholesterol, and high BDI depression scores were significant and independent risk factors for incidence of any proteinuria.
CONCLUSIONS: In African Americans with type 1 diabetes, the 6-year incidence of proteinuria is high, particularly among young patients and those with a relatively short duration of diabetes at baseline. Baseline AER is the strongest predictor for incidence of any proteinuria.

Entities:  

Mesh:

Year:  2007        PMID: 17475942     DOI: 10.2337/dc06-2534

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

Review 1.  Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.

Authors:  Julie A D Van; James W Scholey; Ana Konvalinka
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

2.  Depression and incident diabetic foot ulcers: a prospective cohort study.

Authors:  Lisa H Williams; Carolyn M Rutter; Wayne J Katon; Gayle E Reiber; Paul Ciechanowski; Susan R Heckbert; Elizabeth H B Lin; Evette J Ludman; Malia M Oliver; Bessie A Young; Michael Von Korff
Journal:  Am J Med       Date:  2010-08       Impact factor: 4.965

3.  Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?

Authors:  Joshua I Barzilay; Paul K Whelton; Barry R Davis
Journal:  Ann Transl Med       Date:  2016-05

4.  Depression and incident lower limb amputations in veterans with diabetes.

Authors:  Lisa H Williams; Donald R Miller; Graeme Fincke; Jean-Philippe Lafrance; Ruth Etzioni; Charles Maynard; Gregory J Raugi; Gayle E Reiber
Journal:  J Diabetes Complications       Date:  2010-08-30       Impact factor: 2.852

Review 5.  Early nephropathy in type 1 diabetes: the importance of early renal function decline.

Authors:  Bruce A Perkins; Andrzej S Krolewski
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

6.  Medical and psychological risk factors for incident hypertension in type 1 diabetic african-americans.

Authors:  Monique S Roy; Malvin N Janal; Alec Roy
Journal:  Int J Hypertens       Date:  2011-08-23       Impact factor: 2.420

7.  Racial and ethnic differences in an estimated measure of insulin resistance among individuals with type 1 diabetes.

Authors:  Kirstie K Danielson; Melinda L Drum; Carmela L Estrada; Rebecca B Lipton
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

8.  Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes.

Authors:  Monique S Roy; Malvin N Janal; Juan Crosby; Robert Donnelly
Journal:  Kidney Int       Date:  2014-06-11       Impact factor: 10.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.